Clin2
NCT06892093Possibly a fitRecruiting

Probiotics to prevent diarrhea from neratinib in breast cancer

HER2-positive Breast CancerDiarrhea Caused by DrugNeratinib

Treatments studied

Part of Cancer, Skin clinical trials.

This trial tests whether taking probiotics can help prevent diarrhea caused by the breast cancer drug neratinib. If you are a woman with HER2-positive breast cancer and are about to start neratinib, this study may help manage a common side effect.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
308 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are a woman aged 18 or older with HER2-positive breast cancer.
  • You are scheduled to receive neratinib treatment (alone or with other drugs).
  • You have a good performance status (ECOG 0-2) and expected survival of at least 3 months.
  • Your heart function (LVEF) is 50% or higher, and your liver and kidney blood tests are within acceptable limits.
  • You do not have any ongoing gut problems like chronic constipation, bloody stools, or stomach pain, and no structural gut issues seen on exams.
  • You are not pregnant or breastfeeding and are willing to use effective birth control during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05760612Recruiting· Phase 3
After breast cancer surgery, test neratinib plus trastuzumab

This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.

Guangzhou
NCT07019272Not yet recruiting
Neratinib after standard therapy for high-risk HER2+ breast cancer

This trial tests whether taking neratinib after completing a year of standard treatment can help prevent breast cancer from coming back in women who had a complete response to initial therapy but still have high-risk features.

NCT06693024Recruiting
Neratinib after standard therapy for HER2-positive early breast cancer

This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.

Beijing, Beijing Municipality
NCT07309315Recruiting
Testing a bacteria pill to prevent diarrhea from chemotherapy

This trial tests if a pill made from a harmless bacteria can prevent diarrhea caused by certain chemotherapy treatments. It is for people with advanced colorectal cancer or breast cancer who are about to start specific treatments.

Shenzhen, Guangdong
NCT07605728Recruiting· Phase 2
Probiotics to ease stomach problems from breast cancer treatment

This trial tests whether a special probiotic supplement (good bacteria) can reduce belly discomfort caused by abemaciclib, a hormone therapy drug for early breast cancer. You would take the supplement alongside your cancer treatment to see if it helps with stomach side effects.

Taipei
NCT07264985Recruiting
Gut bacteria and diarrhea in breast cancer patients on pyrotinib

This study looks at how gut bacteria relate to diarrhea in breast cancer patients who are taking a drug called pyrotinib. By understanding this link, doctors hope to better manage side effects in the future.

Wuhan, Hubei

Hear when a new HER2-positive Breast Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.